Datapoint: Appeals Court Invalidates Gilenya Patent

Reversing a lower court decision, a U.S. federal appeals court last week found a key patent for Novartis’ Gilenya invalid, opening the floor for HEC Pharm Co.’s generic challenger. The patent covers the drug’s dosing schedule — 0.5 mg per day — in relapsing multiple sclerosis patients. Novartis says it will contest the ruling. Gilenya was Novartis’ third best-selling drug in 2021, bringing in $2.79 billion in sales. For the treatment of multiple sclerosis, virtually all insured lives (99%) have covered or better access to Gilenya under the pharmacy benefit. 11% of insured lives have preferred access to Gilenya without utilization management restrictions.

SOURCE: MMIT Analytics, as of 6/22/22, and Evaluate Pharma.

0 Comments
AIS Health Staff

AIS Health Staff

Related Posts

businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 17

Datapoint: Humana Inks Deal to Acquire Inclusa

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 16

Datapoint: Mississippi Unveils Medicaid Contract Awards

Read More
businessman-using-laptop-computer-and-digital-tablet-analyzing-sales-data-and-graph-chart
August 15

Datapoint: SCAN Plots MA Expansion Into Texas

Read More

GAIN THERAPEUTIC AREA-SPECIFIC INTEL TO DRIVE ACCESS FOR YOUR BRAND

Sign up for publications to get unmatched business intelligence delivered to your inbox.

subscribe today